Dive into the archives.
- What’s the Point of Extavia?
Featured Story Oct. 16, 2009 By Angela Maas, Managing Editor Another drug in the self-injected multiple sclerosis (MS) class recently came onto the marketplace. But many within the pharmaceutical industry are saying that other than giving Novartis an entry into the MS market before its oral MS therapy gains FDA approval, it is unclear what [...]
- Generic Betaseron Wins FDA Approval
By Eva von Schaper Aug. 17 (Bloomberg) — Novartis AG won U.S. Food and Drug Administration approval to sell its Extavia multiple sclerosis treatment, its brand of Bayer AG’s Betaseron. Extavia, a form of interferon beta-1b, can be used in patients with early and relapsing forms of multiple sclerosis, Basel, Switzerland-based Novartis said in a [...]
